|
[1] BEUERS U, GERSHWIN ME, GISH RG, et al. Changing nomenclature for PBC:From ‘cirrhosis’to ‘cholangitis’[J].Dig Liver Dis, 2015, 47 (11) :924-926.
|
|
[2] LI QQ, ZHOU XM, QI XS, et al. Recommendations for the British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) [J]. J Clin Hepatol, 2018, 34 (6) :1191-1192. (in Chinese) 李谦谦, 周新苗, 祁兴顺, 等.《2018年英国胃肠病学会/英国PBC协作组原发性胆汁性胆管炎治疗及管理指南》推荐意见[J].临床肝胆病杂志, 2018, 34 (6) :1191-1192.
|
|
[3] YOUNOSSI ZM, BERNSTEIN D, SHIFFMAN ML, et al. Diagnosis and management of primary biliary cholangitis[J]. Am J Gastroenterol, 2019, 114 (1) :48-63.
|
|
[4] CARBONE M, MELLS GF, PELLS G, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid[J]. Gastroenterology, 2013, 144 (3) :560-569. e7; quize13-14.
|
|
[5] CHEN S, DUAN W, LI M, et al. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis:A single center follow-up study from China[J]. J Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[6] EASL clinical practice guidelines:The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67 (1) :145-172.
|
|
[7] QUARNETI C, MURATORI P, LALANNE C, et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis[J]. Liver Int, 2015, 35 (2) :636-641.
|
|
[8] LINDOR KD, GERSHWIN ME, POUPON R, et al. Primary biliary cirrhosis[J]. Hepatology, 2009, 50 (1) :291-308.
|
|
[9] API AM, BELSITO D, BOTELHO D, et al. RIFM fragrance ingredient safety assessment, 1-oxaspiro[4. 5]decan-2-one, 8-ethyl-, trans-, CAS Registry Number 91069-40-8[J]. Food Chem Toxicol, 2018, 122 (Suppl 1) :s633-s640.
|
|
[10] KOUROUMALIS E, SAMONAKIS D, VOUMVOURAKI A. Biomarkers for primary biliary cholangitis:Current perspectives[J]. Hepat Med, 2018, 10:43-53.
|
|
[11] VLEGGAAR FP, van BUUREN HR. No prognostic significance of antimitochondrial antibody profile testing in primary biliary cirrhosis[J]. Hepatogastroenterology, 2004, 51 (58) :937-940.
|
|
[12] RIGOPOULOU EI, DAVIES ET, BOGDANOS DP, et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis[J]. Liver Int, 2007, 27 (9) :1226-1231.
|
|
[13] WESIERSKA-GADEK J, PENNER E, BATTEZZATI PM, et al.Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis[J]. Hepatology, 2006, 43 (5) :1135-1144.
|
|
[14] NAKAMURA M, KONDO H, MORI T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology, 2007, 45 (1) :118-127.
|
|
[15] MIYACHI K, HANKINS RW, MATSUSHIMA H, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis:A multicenter study[J]. J Autoimmun, 2003, 20 (3) :247-254.
|
|
[16] TANA MM, SHUMS Z, MILO J, et al. The significance of autoantibody changes over time in primary biliary cirrhosis[J].Am J Clin Pathol, 2015, 144 (4) :601-606.
|
|
[17] JOSHITA S, UMEMURA T, USAMI Y, et al. Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis[J]. Sci Rep, 2018, 8 (1) :8159.
|
|
[18] JOSHITA S, ICHIKAWA Y, UMEMURA T, et al. Serum autotaxin is a useful liver fibrosis marker in patients with chronic hepatitis B virus infection[J]. Hepatol Res, 2018, 48 (4) :275-285.
|
|
[19] HAYASHI M, ABE K, FUJITA M, et al. Changes in serum levels of leucine-richα2-glycoprotein predict prognosis in primary biliary cholangitis[J]. Hepatol Res, 2018.[Epub ahead of print]
|
|
[20] AIBA Y, HARADA K, ITO M, et al. Increased expression and altered localization of cathepsin Z are associated with progression to jaundice stage in primary biliary cholangitis[J]. Sci Rep, 2018, 8 (1) :11808.
|
|
[21] UMEMURA T, JOSHITA S, SEKIGUCHI T, et al. Serum wisteria floribunda agglutinin-positive mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis[J]. Am J Gastroenterol, 2015, 110 (6) :857-864.
|
|
[22] LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149 (7) :1804-1812. e4.
|
|
[23] XING G, PAN L, YI C, et al. Design, synthesis and biological evaluation of 5- (2-amino-1-hydroxyethyl) -8-hydroxyquinolin-2 (1H) -one derivatives as potentβ2-adrenoceptor agonists[J]. Bioorg Med Chem, 2018.[Epub ahead of print]
|
|
[24] HAGA Y, KANDA T, SASAKI R, et al. Serum wisteria floribunda agglutinin-positive mac-2 binding protein could not always predict early cirrhosis in non-viral liver diseases[J].Diseases, 2016, 4 (4) :38.
|
|
[25] HUANG YL, YAO DK, HU ZD, et al. Value of baseline platelet count for prediction of complications in primary biliary cirrhosis patients treated with ursodeoxycholic acid[J]. Scand J Clin Lab Invest, 2013, 73 (1) :17-23.
|
|
[26] LIN L, PIAO M, JIANG X, et al. Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort[J]. BMJ Open, 2017, 7 (7) :e015304.
|
|
[27] CHEUNG KS, SETO WK, FUNG J, et al. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis[J]. World J Gastroenterol, 2017, 23 (44) :7863-7874.
|
|
[28] ALMPANIS Z, DEMONAKOU M, TINIAKOS D. Evaluation of liver fibrosis:“Something old, something new…”[J]. Ann Gastroenterol, 2016, 29 (4) :445-453.
|
|
[29] SHI TY, ZHANG LN, CHEN H, et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis[J].World J Gastroenterol, 2013, 19 (7) :1111-1118.
|
|
[30] HUANG YQ. Recent advances in the diagnosis and treatment of primary biliary cholangitis[J]. World J Hepatol, 2016, 8 (33) :1419-1441.
|
|
[31] FLOREANI A, CAROLI D, VARIOLA A, et al. A 35-year fol owup of a large cohort of patients with primary biliary cirrhosis seen at a single centre[J]. Liver Int, 2011, 31 (3) :361-368.
|
|
[32] MOMAH N, LINDOR KD. Primary biliary cirrhosis in adults[J].Expert Rev Gastroenterol Hepatol, 2014, 8 (4) :427-433.
|
|
[33] SHI J, WU C, LIN Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis:A metaanalysis of randomized controlled trials[J]. Am J Gastroenterol, 2006, 101 (7) :1529-1538.
|
|
[34] TER BPC, SCHALM SW, HANSEN BE, et al. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients[J]. Am J Gastroenterol, 2006, 101 (9) :2044-2050.
|
|
[35] BAHAR R, WONG KA, LIU CH, et al. Update on new drugs and those in development for the treatment of primary biliary cholangitis[J]. Gastroenterol Hepatol (N Y) , 2018, 14 (3) :154-163.
|
|
[36] CARBONE M, SHARP SJ, FLACK S, et al. The UK-PBC risk scores:Derivation and validation of a scoring system for longterm prediction of end-stage liver disease in primary biliary cholangitis[J]. Hepatology, 2016, 63 (3) :930-950.
|
|
[37] ANGULO P, LINDOR KD, THERNEAU TM, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid[J]. Liver, 1999, 19 (2) :115-121.
|
|
[38] PARS A, CABALLERA L, RODS J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid[J]. Gastroenterology, 2006, 130 (3) :715-720.
|
|
[39] CORPECHOT C, ABENAVOLI L, RABAHI N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis[J]. Hepatology, 2008, 48 (3) :871-877.
|
|
[40] KUIPER EM, HANSEN BE, de VRIES RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid[J]. Gastroenterology, 2009, 136 (4) :1281-1287.
|
|
[41] KUMAGI T, GUINDI M, FISCHER SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J]. Am J Gastroenterol, 2010, 105 (10) :2186-2194.
|
|
[42] CORPECHOT C, CHAZOUILLRES O, POUPON R. Early primary biliary cirrhosis:Biochemical response to treatment and prediction of long-term outcome[J]. J Hepatol, 2011, 55 (6) :1361-1367.
|
|
[43] AZEMOTO N, ABE M, MURATA Y, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis[J]. J Gastroenterol, 2009, 44 (6) :630-634.
|
|
[44] YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis:The additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45 (5) :733-743.
|
DownLoad: